Acumen Pharmaceuticals, Inc.
ABOS
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -110.69% | -107.83% | -95.39% | -67.57% | -39.51% |
| Total Depreciation and Amortization | 7.74% | 1.70% | -3.26% | -10.82% | -15.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.00% | 0.00% | -18.53% | 18.45% | 2.22% |
| Change in Net Operating Assets | 122.98% | 3,814.67% | 201.42% | 790.39% | 11,177.27% |
| Cash from Operations | -111.72% | -101.93% | -100.20% | -46.48% | -31.71% |
| Capital Expenditure | -137.84% | -162.50% | 23.81% | 28.57% | 68.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.30% | 161.91% | 127.99% | 78.77% | -2,462.75% |
| Cash from Investing | 177.20% | 161.84% | 127.98% | 78.75% | -2,522.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -99.97% | -99.97% | -93.53% | -93.73% | 3,256.22% |
| Repurchase of Common Stock | 80.57% | 80.57% | 89.49% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.91% | 68.28% | 51.68% | -338.51% | -355.26% |
| Cash from Financing | -100.05% | -100.14% | -95.43% | -71.55% | 4,107.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -243.87% | 45.60% | 50.37% | 1.20% | 73.22% |